NEW YORK (GenomeWeb) – The Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute have partnered with Foundation Medicine on a clinical translation program to develop cancer therapeutics and to expand the utility of Foundation's genomic profiling technologies.
As part of the new program, the Lurie Cancer Center and NMDTI plan to conduct studies with Foundation Medicine that will focus on individualized patient care, matching genomic profiles with investigational therapeutics, and fundamental cancer biology in preclinical models and patient samples.
"Foundation Medicine has already been instrumental to our rapidly expanding programs that offer patients cancer treatment tailored to the specific genomic alterations that drive their malignancies," said Leonidas Platanias, director of the Lurie Cancer Center, in a statement. "This new program reflects our ongoing commitment to being a national leader in the battle to overcome cancer."
"We believe this collaboration will serve to build upon the clinical applications of our products and further expand access to targeted treatment options for patients living with cancer," said Foundation Medicine Chief Medical Officer Vincent Miller in the statement.